Obese women, on average, give birth to babies with high fat mass. Placental lipid metabolism alters fetal lipid delivery, potentially moderating neonatal adiposity, yet how it is affected by maternal obesity is poorly understood. We hypothesized that fatty acid (FA) accumulation (esterification) is higher and FA b-oxidation (FAO) is lower in placentas from obese, compared with lean women. We assessed acylcarnitine profiles (lipid oxidation intermediates) in mother-baby-placenta triads, in addition to lipid content, and messenger RNA (mRNA)/protein expression of key regulators of FA metabolism pathways in placentas of lean and obese women with normal glucose tolerance recruited at scheduled term Cesarean delivery. In isolated trophoblasts, we measured [ 3 H]-palmitate metabolism. Placentas of obese women had 17.5% (95% confidence interval: 6.1, 28.7%) more lipid than placentas of lean women, and higher mRNA and protein expression of FA esterification regulators (e.g., peroxisome proliferator-activated receptor g, acetyl-CoA carboxylase, steroyl-CoA desaturase 1, and diacylglycerol O-acyltransferase-1). [ 3 H]-palmitate esterification rates were increased in trophoblasts from obese compared with lean women. Placentas of obese women had fewer mitochondria and a lower concentration of acylcarnitines, suggesting a decrease in mitochondrial FAO capacity. Conversely, peroxisomal FAO was greater in placentas of obese women. Altogether, these changes in placental lipid metabolism may serve to limit the amount of maternal lipid transferred to the fetus, restraining excess fetal adiposity in this population of glucose-tolerant women. (Endocrinology 158: 2543(Endocrinology 158: -2555(Endocrinology 158: , 2017 S ixty percent of women who become pregnant in the United States are overweight or obese [body mass index (BMI) .25 kg/m 2 ] (1). Offspring of obese women have a greater risk of developing obesity and cardiovascular disease in later life (2, 3). Impaired placental function of obese women may mediate these poor outcomes by altering the supply of key nutrients, such as long-chain fatty acids (FA) to the fetus (4, 5). Placentas of obese women are characterized by lipid accumulation, inflammation, and oxidative stress (6, 7). The driver of this lipotoxic environment, high placenta lipid content, is not explained by enhanced uptake, as long-chain FA uptake is generally decreased in placentas of obese women (8, 9). However, changes in placental FA metabolism, such as decreased FA b-oxidation (FAO) and/or increased esterification, determine the fate of intracellular FA, ultimately affecting fetal FA delivery, and altering growth, fat accretion, and development (5, 10).
3
H]-palmitate esterification rates were increased in trophoblasts from obese compared with lean women. Placentas of obese women had fewer mitochondria and a lower concentration of acylcarnitines, suggesting a decrease in mitochondrial FAO capacity. Conversely, peroxisomal FAO was greater in placentas of obese women. Altogether, these changes in placental lipid metabolism may serve to limit the amount of maternal lipid transferred to the fetus, restraining excess fetal adiposity in this population of glucose-tolerant women. (1). Offspring of obese women have a greater risk of developing obesity and cardiovascular disease in later life (2, 3) . Impaired placental function of obese women may mediate these poor outcomes by altering the supply of key nutrients, such as long-chain fatty acids (FA) to the fetus (4, 5) . Placentas of obese women are characterized by lipid accumulation, inflammation, and oxidative stress (6, 7) . The driver of this lipotoxic environment, high placenta lipid content, is not explained by enhanced uptake, as long-chain FA uptake is generally decreased in placentas of obese women (8, 9) . However, changes in placental FA metabolism, such as decreased FA b-oxidation (FAO) and/or increased esterification, determine the fate of intracellular FA, ultimately affecting fetal FA delivery, and altering growth, fat accretion, and development (5, 10) .
Our group and others have reported reduced mitochondrial function and/or number in placentas of obese, compared with lean women (11) (12) (13) . As mitochondria are the major site of FAO (14) , these findings suggest that placental FAO may be impaired in obese women. Longchain FA (.14 carbons) must be esterified to carnitine prior to transport across the inner mitochondrial membrane for subsequent b-oxidation. Activity of mitochondrial enzymes [e.g., carnitine palmitoyltransferase (CPT)1] that synthesize these acylcarnitines (ACs) regulates b-oxidation rates (15, 16) . Ryckman et al. (17) recently reported that obese women have higher plasma long-chain AC concentrations compared with lean women during pregnancy; however, a larger study by Hellmuth et al. (18) found no association between maternal obesity and AC concentrations. Placental AC content, reflecting local FAO capacity/activity, was not assessed in either study. Under conditions of lipid oversupply (e.g., obesity), peroxisomes enhance cellular FAO capacity by shortening long-chain FA, allowing them to bypass CPT1 and enter mitochondria for complete oxidation (19) . Peroxisomal proliferation is stimulated by high FA concentrations (20) , suggesting that, in the setting of obesity and hyperlipidemia, these organelles may play an important role in cellular metabolism, although their placental activity in obese women is unknown.
To test the hypothesis that placental FAO capacity is impaired and FA esterification is enhanced in obese women, we assessed the following: (1) AC profiles, lipid content, and expression of key components of FA esterification and oxidation pathways in placentas of lean and obese women, and (2) [ 3 H]-palmitate oxidation and esterification in trophoblasts isolated from placentas of lean and obese women.
Materials and Methods

Study design
We performed a cross-sectional study of healthy women recruited at 38 to 40 weeks of pregnancy who delivered by scheduled cesarean section at MetroHealth Medical Center (Cleveland, OH). Women were grouped by prepregnancy BMI (lean: ,25 kg/m 2 , n = 40 and obese .30 kg/m 2 , n = 40). Group size was based upon our previous study (10) of placental metabolism in fish oil-supplemented patients at MetroHealth Medical Center. Subjects with fetal anomalies, multiple gestations, pre-eclampsia, diabetes (pre-existing and gestational), or other comorbid disease were excluded. Placental tissue was collected at the time of delivery from the maternal face of the placenta avoiding calcified or underperfused cotyledons. Several full-depth samples were collected randomly across the surface of the placenta from multiple cotyledons. Chorionic membranes and maternal decidua layers were removed, and large villous samples were further dissected into small pieces that were blotted for removal of blood and separately snap frozen in liquid nitrogen within 5 minutes of biopsy. Maternal and cord blood were collected and processed, as previously described (11) .
Blood glucose, insulin, and free FA concentrations were measured, and homeostasis model assessment-estimated insulin resistance (HOMA-IR) was calculated, as described previously (11) . Neonatal anthropometrics (birth weight, length, skin folds) were collected within 48 hours of birth. Neonatal lean body mass, fat mass, and percentage of fat were calculated from skin fold data, as previously described (21) . The study was conducted according to the guidelines in the Declaration of Helsinki. Written and informed consent was obtained prior to participation, and the study was approved by the Institutional Review Board of MetroHealth Medical Center/Case Western Reserve University (IRB 1300650).
Placental lipid analysis
Total lipids were extracted from 80 to 100 mg frozen placental tissue with chloroform:methanol [2:1 volume-to-volume ratio (v/v)], as previously described (10, 22) , and normalized to tissue weight. Data were expressed as total extractable lipids/g tissue.
Separation of phospholipids (PL) and neutral lipid species was performed on thin-layer chromatography (TLC) plates (TLC-precoated silica gel 60 F254 plates; Millipore, Billerica, MA). TLC plates were prewashed by an ascending development up to 1 cm from the top in a clean tank containing a mixture of chloroform:methanol (1:1, v/v). Plates were air dried in a fume hood for 30 minutes to remove any material interfering with further quantitative and qualitative analyses. Before use, plates were completely wetted with 2.3% boric acid, drained for 5 minutes in a fume hood, and dried at l00°C for 15 minutes. A total of 2 ml each sample and 1 ml standards in chloroform was spotted 1 cm from the edge of the plate in 1-cm bands. Plates were developed in a stepwise fashion in chambers saturated with the following: 1) chloroform-methanol-water 60:30:5 (v/v/v) up to the middle of the plate; and 2) hexane-diethyl ether-acetic acid 80:20:1.5 (v/v) up to 1 cm from the top. After separation, lipids were charred by spraying the plate with phosphomolybdic acid solution (Sigma-Aldrich, St. Louis, MO), thoroughly air dried in a fume hood, and immediately heated at 200°C for 2 to 4 minutes. An image of the plate was acquired with ChemiDocIt TS2 810 imager (UVP, Upland, CA). Lipid spots were quantified using UVP VisionWorksLS software. Total of lipid fractions per sample was considered 100%, and each lipid fraction was calculated based on amount of lipid applied and normalized to grams of starting tissue. Standards for each of the lipid classes were applied to every plate [cholesteryl oleate, triolein, oleic acid, free cholesterol, and 1,2 distearolyl, 18-5a, Nu-chek Prep, Elysian, MN; phosphatidylethanolamine (PE), phosphatidylcholine (PC), lysophosphatidylcholine, all from egg yolk; phosphatidylinositol from soybean, and cardiolipin from bovine heart, Sigma-Aldrich].
Immunohistochemical staining for peripilin 2
The placenta samples from both lean and obese patients that had been flash frozen in liquid nitrogen and stored at 280°C were used in this study. The samples were cryosectioned and mounted on Superfrost Plus Slides (Fisher Scientific, Waltham, MA) and, after air drying at room temperature, were placed in ice-cold 4% paraformaldehyde/0.1 M phosphate buffer (Electron Microscopy Sciences, Hatfield, PA) for 30 minutes. After rinsing in phosphate-buffered saline (PBS), the slides were blocked for nonspecific staining with 10 mM phosphate buffer containing 1% bovine serum albumin (BSA; Jackson ImmunoResearch, West Grove, PA), 0.3% Triton X-100, and 5% normal donkey serum (Jackson ImmunoResearch) for CPT1b, PPARa, acyl-coenzyme A dehydrogenase, very long chain, carnitine/AC translocase (CACT), carnitine O-palmitoyltransferase 2, and organic cation/carnitine transporter 2; FA oxidation (peroxisomal): peroxisomal biogenesis factor 3, D-bifunctional protein (DBP), and peroxisomal carnitine O-octanoyltransferase (COT). Placental mitochondrial biogenesis and number were assessed by messenger RNA (mRNA) expression of PPARg coactivator 1a (PGC1-a, a transcriptional coactivator required for mitochondrial biogenesis) for the quantitative determination of mitochondrial DNA (mtDNA) content of cytochrome B (CytB) relative to nuclear (b-actin) DNA, as described previously (11) .
Primer sequences are shown in Supplemental Table 1 . The cycling conditions for the real-time PCR were the same for all primer pairs: 1) 95°C for 10 minutes; 2) 40 cycles of 95°C 20 seconds, 55°C for 30 seconds, and 72°C for 30 seconds; and 3) final elongation at 72°C for 10 minutes. For each primer pair, a standard curve including no template control and unknowns was run in triplicate. The melt curve of the resulting amplicon was analyzed to ensure that a single product was detected for each replicate, and data were analyzed using Roche LightCycler 480 software (v 1.5.1), as described previously (10) . L19 was used as a reference gene because no association between maternal obesity and L19 expression within the placenta was observed. Values were expressed as a ratio of the gene of interest:reference in each sample.
For determination of mtDNA number, genomic DNA was isolated from frozen placental tissue (20 mg) using a Qiagen DNeasy kit. Amplifications were performed in duplicate using 200 ng genomic DNA. Standard curves for mitochondrial CytB and nuclear b-actin were generated using female genomic DNA. For the determination of mtDNA content relative to nuclear DNA, mitochondrial CytB in each sample was normalized against nuclear b-actin.
Western blotting
To further confirm the association between maternal obesity and regulators of lipid metabolism, Western blotting was performed in a subset of samples (n = 7 lean and n = 7 obese). Briefly, 20 mg total protein was separated on a 10% sodium dodecyl sulfate-polyacrylamide gel and electrotransferred onto a nitrocellulose membrane. After blocking the membrane with 5% milk PBS-T buffer, it was incubated with primary antibody rabbit antiPPARg ( After washing with PBS-T, the membrane was exposed to the antirabbit secondary antibody (1:2000 to 1:7000, catalog sc-2004, RRID: AB_631746; Cell Signaling) for 1 hour at room temperature. Protein expression of CPT1b was also measured in isolated mitochondrial extracts under similar conditions. b-actin and voltagedependent anion channel were the housekeeping proteins used to normalize the data for placenta and mitochondria, respectively. Values were expressed as the ratio between protein of interest and housekeeping protein expression. Image was detected using enhanced chemiluminescence (Amersham, Pittsburg, PA) and edited using NIH ImageJ software (v 1.48).
Carnitine and AC analysis
Carnitine and AC (lipid oxidation intermediates) were quantified in plasma and tissue in mother-baby-placenta triads by mass spectrometry, as described previously (23, 24) , in a subset of nine lean (pregravid BMI = 21.8 6 3.1 kg/m 2 ) and nine obese (39.6 6 7.2 kg/m 2 ) women.
Isolation of human trophoblast cells
To determine the effect of maternal obesity on lipid metabolism activity at the cellular level in placental tissue, human trophoblast cells were freshly isolated from n = 12 lean and n = 13 obese women with a singleton pregnancy recruited at term (38 to 40 weeks) prior to an elective cesarean section. This separate study was approved by the Institutional Review Board of MetroHealth Medical Center, Case Western Reserve University (IRB 1300650), and written informed consent was obtained prior to collecting placental tissue. Maternal and cord blood and neonatal anthropometrics were collected, as described above. Trophoblasts were isolated by sequential trypsin and DNase digestion, followed by gradient centrifugation, as described previously (10, 25) . Cells were seeded into six-well plates at a density of 3 3 10 6 cells/well and cultured overnight in Iscove's modified Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum and 1% penicillin/ streptomycin and maintained at 37°C under 5% CO 2 . Each assay was performed in triplicate.
FA esterification into total lipids in trophoblast cells
FA esterification in isolated placental trophoblast cells was determined, as described previously (10) . Briefly, trophoblast cells were incubated in culture medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin in the presence of 1.25% BSA, 0.1 mmol/L unlabeled palmitate, and 18,500 Bq/mL [ 3 H]-palmitate (100 mM) for 18 hours at 37°C under 5% CO 2 . At the end of the treatment period, trophoblast cells were washed with ice-cold PBS and homogenized in 200 mL high-performance liquid chromatography-grade acetone. Following lipid extraction, radioactivity in a 100 mL aliquot, representing esterified palmitate, was counted on a Beckman LS3801 liquid scintillation counter (Beckman Coulter, Brea, CA). An additional aliquot was used to determine total proteins using the bicinchoninic acid method (Sigma-Aldrich). Esterification was calculated as nmol palmitate/mg protein/h. The [9,10-[ 3 H]]-almitic acid was from Movarek Biochemicals (Brea, CA), and FA-free BSA was from Sigma-Aldrich.
FA oxidation assay in human trophoblast cells
FAO assays were performed in vitro in isolated placental trophoblast cells, as described previously, with some modifications (10 Placentas from five lean and four obese women were used to assess mitochondrial vs peroxisomal FAO capacity because both organelles play an important role in FAO. Placental trophoblast cells were incubated in the conditions described for esterification and FAO in the absence or presence of 200 mM Etomoxir (a specific and irreversible inhibitor of CPT1), therefore limiting the entry of FA to the mitochondria for oxidation. FA esterification and oxidation were assessed, as described above.
Statistics
All data in tables and text are presented as means 6 standard deviation, and in figures as mean 6 standard error of the mean, unless noted otherwise. Results of the mRNA and protein quantification were expressed in arbitrary units and normalized (by natural log transformation) before analysis. Differences between groups were analyzed using the nonparametric Mann-Whitney U test. Correlations between lipid content, mRNA expression, and carnitine concentration were assessed using Spearman's correlation. For multivariate regression analyses, all data were first tested for normality via Shapiro-Wilk's test and log transformed if necessary. Etomoxir data were analyzed via one-sample t test. Statistical analysis was performed using GraphPad Prism (version 6; La Jolla, CA). P values ,0.05 were considered statistically significant.
Results
Demographic data of the cohort are summarized in Table 1 . There were no significant differences in parity, maternal, or gestational age at delivery. HOMA-IR, glucose, and insulin concentrations in maternal blood were significantly higher in the obese than in the lean group (P , 0.05). Neonatal birth weight, fat, lean body mass, and placental weights were not significantly different between groups in this cohort of women. As groups differed by maternal race and gestational weight gain, which may impact fetal growth, we used multiple linear regression to adjust for these and other relevant factors. Following adjustment for these potential confounding variables (maternal age, parity, race, gestational weight gain, and fetal sex), placental weight, birth weight, and fat-free mass were significantly higher in obese vs lean women (Table 1) . HOMA-IR in cord blood was significantly higher in the offspring of obese compared with lean women (P , 0.05). Neither cord nor maternal free FA was different between groups. We did not detect any gender effect on any of these outcomes (see Supplemental Table 2 for breakdown of groups by fetal sex).
Maternal obesity is associated with increased placental lipid content
To determine the effect of maternal obesity on placental lipid content, total lipids were extracted from placentas of lean (n = 34) and obese (n = 39) women. The placentas from obese women had 17% more total lipid than placentas from lean women (22.9 6 5.2 vs 19.5 6 4.1 mg lipid/g tissue; P = 0.002) [ Fig. 1(a) ]. Adjustment for maternal age, parity, gestational weight gain, race, or fetal sex did not affect this association. TLC was used to separate placental total lipid into PL and neutral lipid components (Supplemental Fig. 1 ). Placentas from obese women had 20% more esterified lipids (cholesterol esters, triglycerides, PE, and PC) than placentas of lean women (Table 2 ). Free FA content was not statistically different between groups. Lipid droplets, visualized via perilipin 2 [a component of lipid droplet membranes (27) ] staining, were localized largely to the syncytiotrophoblast layer of the term placenta [ Fig. 1b) ].
Maternal obesity is associated with increased placental lipid esterification gene and protein expression
To gain further insight into the molecular mechanisms underlying lipid accumulation in placentas of obese women, we measured the expression of placental genes and proteins involved in FA esterification. As shown in Fig. 2(a) , placental mRNA expression of ACC, PPARg, SCD1, and DGAT1 was significantly higher in placentas from obese women compared with lean women (P , 0.05), and gene expression was positively correlated with placental lipid content (ACC: Spearman r = 0.240, 95% CI: 0.02, 0.452, P = 0.042; PPARg: r = 0.256, 95% CI: 0.020, 0.464, P = 0.029). Gene expression remained statistically different between lean and obese groups following adjustment for maternal age, race, gestational weight gain, parity, and fetal sex, except for SCD1 (P = 0.056). In addition, placental PPARg, SCD1, and DGAT1 protein concentrations were higher in obese women [ Fig. 2(b) and 2(c) ]. We did not detect any gender differences in any of these outcomes (Supplemental Table 3 ).
Effect of maternal obesity on placental FA oxidation gene and protein expression
Because 95% of FAO occurs in the mitochondria (14), we estimated placental mitochondrial biogenesis and number by measuring PGC1-a [a master regulator of mitochondrial biogenesis (28)] mRNA expression, and mtDNA relative to nuclear DNA (CytB/b-actin) (11), respectively. Based on these markers, maternal obesity was associated with reduced placental mitochondrial biogenesis and number [P , 0.05, Fig. 3(a) ]. In addition, placental mRNA expression of PPARa, and its target gene CPT1b, was significantly lower in obese compared with lean women [ Fig. 3(a) ]. Placental PPARa protein levels were also reduced in obese mothers [ Fig. 3(b) and  3(c) ]. CPT1b protein levels were not significantly affected by maternal obesity in whole tissue [ Fig. 3(b) ] or isolated mitochondria (data not shown). Placental mRNA expression of PPARa was negatively correlated with placental lipid content (r = 20.256, 95% CI: 20.464, 20.020, P = 0.029).
Placental and umbilical venous plasma AC are lower in obese women
Total carnitine content [AC + free carnitine (FC)] and short-and medium-chain AC were decreased in placentas of obese women (P , 0.05) ( Table 3 ). The placental AC/ FC ratio was significantly higher in obese women (1.43 6 0.22 vs 1.14 6 0.21, P = 0.009), suggesting a decreased mitochondrial capacity for energy production (15) . Consistent with its role in AC formation, placental CPT1 expression was positively correlated with total placental Table 4 ). Umbilical cord plasma total carnitine and mediumchain AC were significantly reduced in offspring of obese women (P , 0.05). Umbilical cord carnitine content may reflect spillover from the placenta, as rates of fetal FAO are very low (29, 30) . We were unable to detect differences in maternal plasma FC or AC content between lean and obese women.
The placental mRNA expression of CACT and CPT2 (members of the carnitine shuttle involved in transport of AC and FC across the inner mitochondrial membrane), and organic cation/carnitine transporter 2 (the plasma membrane carnitine transporter), was significantly higher in placentas from obese vs lean women [ Fig. 3(a) ].
Effect of maternal obesity on placental lipid esterification and FAO in vitro
To determine the effect of the aforementioned molecular changes on cellular metabolism, we measured [ 3 H]-palmitate oxidation and esterification rates in freshly isolated trophoblast cells (the most metabolically active cells in the placenta) from a separate cohort of healthy lean (n = 14) and obese (n = 15) women. Maternal and neonatal metabolic characteristics (Table 4) were similar to women included in the larger cohort. As shown in Fig. 4(a) isolated trophoblast cells was not significantly affected by maternal obesity [Fig. 4(b) ]. Long-chain FA, such as palmitate, require conversion to their AC via CPT1 to enter mitochondria for FAO. Alternatively, they may be partially oxidized in nearby peroxisomes, the newly shortened FA, then able to bypass CPT1 and enter the mitochondria for complete oxidation (31) . We used etomoxir (a specific and irreversible inhibitor of CPT1) (32) to measure the rate of [ 3 H]-palmitate oxidation in the absence of the typical mitochondrial pathway-representing the peroxisomal contribution to FAO (33) . CPT1 inhibition had a weaker effect on cellular FAO rates in obese compared with lean women (82.9 6 3.3% vs 92.2 6 1.2% inhibition, P , 0.05), suggesting that extramitochondrial (peroxisomal) FAO capacity is greater in trophoblasts of obese women [ Fig. 4(c) ]. Consistent with enhanced peroxisomal activity, placental mRNA expression of DBP and COT (key enzymes regulating peroxisomal b-oxidation of FA) was significantly increased in obese compared with lean women [P , 0.05, Fig. 3(a) ].
Discussion
Placental lipid metabolism is critical for placental function and positive pregnancy outcomes and affects fetal growth (4, 34) . This study uses multiple molecular approaches (i.e., labeled lipid tracers, chromatography, quantitative PCR, immunohistochemistry, Western blotting) to characterize lipid metabolism in placentas of healthy lean and obese women. Our key finding is that maternal obesity is associated with an increase in lipid esterification and storage, and a decrease in mitochondrial FAO, which is compensated for by an upregulation of peroxisomal FAO. Altogether, these changes may serve to limit the amount of maternal lipid transferred to the fetus. Consistent with previous reports (6, 7), lipid content was higher in placentas from obese as compared with lean women. Our data suggest this is secondary to an upregulation in expression of key proteins in the lipid esterification pathway (e.g., PPARg, DGAT1, SCD1), driving FA taken up by the trophoblast toward esterification The causal mechanism driving the upregulation of the esterification pathway in placentas of obese women is not known. PPARg, a lipid-activated transcription factor, regulates the expression of lipid esterification and storage genes in several tissues (37) (38) (39) and was upregulated in placentas of obese women. Placental FA concentrations may be elevated in obese women due to either increased maternal supply, secondary to maternal insulin resistance and increased lipolysis (40) , or lower placental FA oxidation. We speculate that elevated FA concentrations within the placenta activate PPARg. In turn, PPARg stimulates the transcription of DGAT1, SCD1, and ACC, key genes involved in lipid esterification and storage (37, 41, 42) . Further studies are necessary to confirm this hypothesis in placental tissue, although others have described such a mechanism in adipose and hepatic tissues in mice and nonpregnant subjects (38, 39) . Interestingly, in a mouse model, rosiglitazone-induced placental PPARg activation resulted in higher placental FA uptake, but lower transfer to the fetus, due to increased lipid storage in the placenta (38) . Indeed, based on our findings that higher placental lipid content correlated with lower neonatal fat mass and percent body fat, we speculate that higher placenta lipid storage partially protects the fetus from excess maternal lipid supply in obese pregnancies. In our model, 8% of variation in neonatal adiposity could be explained by placental lipid content. These results support the idea that the mother buffers the effects of the ex utero environment on the developing fetus (43, 44) . Impairments in this feto-protective mechanism (e.g., inhibition of esterification pathways) may expose the fetus to excess maternal lipids, potentially explaining our recent finding that fish oil supplementation in obese women, which lowered placental lipid content, was associated with higher, not lower, neonatal fat mass (10) . In addition to influencing tissue FA content and their availability for esterification and storage, FA oxidation within the placenta provides ATP for critical placental functions such as hormone synthesis, which controls maternal adaptations to pregnancy and parturition (11, (45) (46) (47) . We found that expression of CPT1, which catalyzes the rate-limiting step in mitochondrial FAO (35, 48) , and PPARa, a positive regulator of CPT1 transcription (49) , was lower in placentas of obese women, in addition to markers of mitochondrial biogenesis (PGC1-a) and number (CytB). These molecular indicators of placental FAO capacity were further validated by the quantity of the FAO intermediates, AC. The strong positive correlation between CPT1 mRNA expression and total AC concentration in the placenta demonstrates the importance of CPT1 for AC synthesis (50). Although we did not detect a decrease in protein expression, the reduction in placental AC content in obese women suggests that CPT1 activity was impaired. Upregulation of genes involved in the mitochondrial carnitine shuttle (e.g., CACT, CPT2) may indicate a compensatory response to the low AC concentration, attempting to boost mitochondrial AC uptake to maintain FAO.
To assess the outcome of these molecular changes on FAO activity, we measured the oxidation of [ 3 H]-palmitate in trophoblasts isolated from an independent cohort of lean and obese women. We were unable to detect significant changes in the rate of palmitate oxidation between groups. Although mitochondria are responsible for 95% of cellular FAO, peroxisomes can also oxidize lipids (51) . Peroxisomal participation in FAO may be enhanced in the setting of a high-fat diet or obesity in some tissues (20, 52) . We used etomoxir, a specific and irreversible inhibitor of CPT1, to block mitochondrial long-chain FAO in isolated trophoblasts, and assessed the rate of palmitate oxidation. Etomoxir inhibited palmitate oxidation 92% in trophoblasts from lean women, but only 83% in trophoblasts from obese women. This indicates that the extramitochondrial contribution (peroxisomal) to FAO in placentas of obese women is ;10% greater and may compensate for the reduced mitochondrial number or function, thereby maintaining overall placental lipid oxidation capacity (depicted in Fig. 5 ). Consistent with this, peroxisomal FAO enzymes [e.g., COT, DBP (19, 53) ] were more highly expressed in placentas of obese women. Although an increase in peroxisomal function can maintain crucial FAO capacity, the byproduct of peroxisomal FAO is hydrogen peroxide (H 2 O 2 ), an oxidant that may damage the mitochondria, particularly if cellular antioxidant production is inadequate, as has been reported in placentas of obese women (6, 12) , thus leading to further cellular damage.
Our study has several strengths, such as the use of mRNA, protein, and in vitro activity assays to assess metabolic pathways, in two independent cohorts. However, our conclusions are limited by the fact that we are only studying the placenta at term. Further prospective studies are necessary to determine the ontogeny of alterations in placental lipid metabolism in pregnancies complicated by obesity and diabetes. Figure 5 , a depiction of how FA metabolism pathways are altered in placentas of obese women, summarizes our findings. We found that extramitochondrial (peroxisomal) FAO was enhanced in placentas of obese women, compensating for impaired mitochondrial function. Additionally, placenta lipid esterification and storage were greater. These adaptations of placental lipid metabolism pathways in obese women may limit excess fetal fat delivery, although further work on placenta FA flux throughout gestation among these women is necessary.
